AU2019341000B2 - Composition for inducing death of cells having mutated gene, and method for inducing death of cells having modified gene by using composition - Google Patents
Composition for inducing death of cells having mutated gene, and method for inducing death of cells having modified gene by using composition Download PDFInfo
- Publication number
- AU2019341000B2 AU2019341000B2 AU2019341000A AU2019341000A AU2019341000B2 AU 2019341000 B2 AU2019341000 B2 AU 2019341000B2 AU 2019341000 A AU2019341000 A AU 2019341000A AU 2019341000 A AU2019341000 A AU 2019341000A AU 2019341000 B2 AU2019341000 B2 AU 2019341000B2
- Authority
- AU
- Australia
- Prior art keywords
- sequence
- cells
- dna
- nucleic acid
- nuclease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20180109214 | 2018-09-12 | ||
KR10-2018-0109214 | 2018-09-12 | ||
PCT/KR2019/011866 WO2020055187A1 (ko) | 2018-09-12 | 2019-09-11 | 유전자가 변이된 세포의 사멸 유도 조성물 및 상기 조성물을 이용한 유전자가 변형된 세포 사멸 유도 방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2019341000A1 AU2019341000A1 (en) | 2021-05-20 |
AU2019341000B2 true AU2019341000B2 (en) | 2023-03-16 |
Family
ID=69776723
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2019341000A Active AU2019341000B2 (en) | 2018-09-12 | 2019-09-11 | Composition for inducing death of cells having mutated gene, and method for inducing death of cells having modified gene by using composition |
Country Status (9)
Country | Link |
---|---|
US (1) | US20220049274A1 (ko) |
EP (1) | EP3851528A4 (ko) |
JP (1) | JP7410154B2 (ko) |
KR (2) | KR102131869B1 (ko) |
CN (1) | CN112955550A (ko) |
AU (1) | AU2019341000B2 (ko) |
CA (1) | CA3111477A1 (ko) |
EA (1) | EA202190758A1 (ko) |
WO (1) | WO2020055187A1 (ko) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115397997A (zh) * | 2020-12-23 | 2022-11-25 | 浙江大学 | 侵染性植物弹状病毒载体及无转基因植物基因组定点编辑的方法 |
CN113897386A (zh) * | 2021-08-03 | 2022-01-07 | 南京景瑞康分子医药科技有限公司 | 一种利用rna干扰机制诱导多位点切割基因组实现选择性杀死细胞的dna系统 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015159068A1 (en) * | 2014-04-14 | 2015-10-22 | Nemesis Bioscience Ltd | Therapeutic |
US20170145405A1 (en) * | 2015-11-25 | 2017-05-25 | The Board Of Trustees Of The Leland Stanford Junior University | Crispr/cas-mediated genome editing to treat egfr-mutant lung cancer |
WO2018009525A1 (en) * | 2016-07-05 | 2018-01-11 | The Johnson Hopkins University | Crispr/cas9-based compositions and methods for treating cancer |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0405985D0 (en) * | 2004-03-17 | 2004-04-21 | Novartis Forschungsstiftung | Kinase |
EP2520652B1 (en) * | 2004-04-09 | 2015-06-10 | Genecare Research Institute Co., Ltd | Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associates genes |
JP2013527248A (ja) * | 2010-06-04 | 2013-06-27 | オンコシレオン インク. | ウォルトマンニンアナログによる癌の処置 |
AU2012315384B2 (en) * | 2011-09-30 | 2017-08-10 | Vertex Pharmaceuticals Incorporated | Treating pancreatic cancer and non-small cell lung cancer with ATR inhibitors |
DE202013012610U1 (de) * | 2012-10-23 | 2017-11-24 | Toolgen, Inc. | Zusammensetzung zum Spalten einer Ziel-DNA, umfassend eine für die Ziel-DNA spezifische guide-RNA und eine Cas-Protein-codierende Nukleinsäure oder ein Cas-Protein, sowie deren Verwendung |
WO2016014148A1 (en) * | 2014-07-23 | 2016-01-28 | Mayo Foundation For Medical Education And Research | Targeting dna-pkcs and b7-h1 to treat cancer |
WO2016094888A1 (en) * | 2014-12-12 | 2016-06-16 | James Zhu | Methods and compositions for selectively eliminating cells of interest |
US10166255B2 (en) * | 2015-07-31 | 2019-01-01 | Regents Of The University Of Minnesota | Intracellular genomic transplant and methods of therapy |
WO2017074788A1 (en) * | 2015-10-27 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for targeting cancer-specific sequence variations |
CN107303291A (zh) * | 2016-04-18 | 2017-10-31 | 无锡杰西医药股份有限公司 | 含peitc的药物组合物及其在癌症治疗中的应用 |
CN110114461A (zh) * | 2016-08-17 | 2019-08-09 | 博德研究所 | 新型crispr酶和系统 |
-
2019
- 2019-09-11 KR KR1020190112763A patent/KR102131869B1/ko active IP Right Grant
- 2019-09-11 CA CA3111477A patent/CA3111477A1/en active Pending
- 2019-09-11 EP EP19860511.5A patent/EP3851528A4/en active Pending
- 2019-09-11 US US17/276,090 patent/US20220049274A1/en active Pending
- 2019-09-11 AU AU2019341000A patent/AU2019341000B2/en active Active
- 2019-09-11 CN CN201980071309.0A patent/CN112955550A/zh active Pending
- 2019-09-11 WO PCT/KR2019/011866 patent/WO2020055187A1/ko unknown
- 2019-09-11 JP JP2021539322A patent/JP7410154B2/ja active Active
- 2019-09-11 EA EA202190758A patent/EA202190758A1/ru unknown
-
2020
- 2020-07-02 KR KR1020200081538A patent/KR20200084843A/ko active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015159068A1 (en) * | 2014-04-14 | 2015-10-22 | Nemesis Bioscience Ltd | Therapeutic |
US20170145405A1 (en) * | 2015-11-25 | 2017-05-25 | The Board Of Trustees Of The Leland Stanford Junior University | Crispr/cas-mediated genome editing to treat egfr-mutant lung cancer |
WO2018009525A1 (en) * | 2016-07-05 | 2018-01-11 | The Johnson Hopkins University | Crispr/cas9-based compositions and methods for treating cancer |
Also Published As
Publication number | Publication date |
---|---|
US20220049274A1 (en) | 2022-02-17 |
KR102131869B1 (ko) | 2020-07-09 |
EP3851528A1 (en) | 2021-07-21 |
CN112955550A (zh) | 2021-06-11 |
JP2022502481A (ja) | 2022-01-11 |
KR20200084843A (ko) | 2020-07-13 |
AU2019341000A1 (en) | 2021-05-20 |
EA202190758A1 (ru) | 2021-08-03 |
JP7410154B2 (ja) | 2024-01-09 |
CA3111477A1 (en) | 2020-03-19 |
KR20200030474A (ko) | 2020-03-20 |
WO2020055187A1 (ko) | 2020-03-19 |
EP3851528A4 (en) | 2023-12-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7431891B2 (ja) | 化学的に修飾されたガイドrnaを使用する高特異性ゲノム編集 | |
Bernstein et al. | TALE-mediated epigenetic suppression of CDKN2A increases replication in human fibroblasts | |
TWI716367B (zh) | 用於常間回文重複序列叢集(crispr)之大量平行組合性基因學 | |
US20200048716A1 (en) | Using minivectors to treat ovarian cancer | |
AU2019341000B2 (en) | Composition for inducing death of cells having mutated gene, and method for inducing death of cells having modified gene by using composition | |
US7972816B2 (en) | Efficient process for producing dumbbell DNA | |
TW201842923A (zh) | 包含mir-302前驅體的組合物在製造用於肺癌治療之藥物上的用途 | |
Wang et al. | CRISPR-Cas9 HDR system enhances AQP1 gene expression | |
Demin et al. | Adversary of DNA integrity: A long non‐coding RNA stimulates driver oncogenic chromosomal rearrangement in human thyroid cells | |
CN115485385A (zh) | 用于使肿瘤细胞对免疫疗法敏感的方法和组合物 | |
KR102679172B1 (ko) | 질환 세포-특이적인 miRNA에 의해 세포 생리 활성 조절 물질의 활성을 조절하는 복합체 및 이를 CRISPR/Cas 시스템에 적용한 질환 특이적 유전자 조작용 복합체 | |
EA047138B1 (ru) | Композиция для индукции гибели клеток, имеющих мутированный ген, и способ индукции гибели клеток, имеющих мутированный ген, с применением композиции | |
García-Tuñon et al. | CRISPR-ERA for switching off (onco) genes | |
WO2022052909A1 (zh) | 编辑造血干/祖细胞中bcl11a基因的方法 | |
JP7422128B2 (ja) | 配列特異的なインビボ細胞標的化 | |
Garcia | Functional relevance of MCL1 alternative 3'UTR mRNA isoforms in human cells | |
JP4496362B2 (ja) | 抗癌剤の効果を判定するミトコンドリアdnaの体細胞変異の検出 | |
US20240240208A1 (en) | Compositions and methods for increasing efficiency of precise editing repair | |
EP4342986A1 (en) | Composition and method for treatment of lca10 using rna-guided nuclease | |
TW202419631A (zh) | 新的基因組安全港及其用途 | |
Bhavsar et al. | A review on CRISPR-Cas9 and its role in cancer immunotherapy | |
Kim et al. | Selective regression of cells expressing mouse cytoskeleton-associated protein 2 transcript by trans-splicing ribozyme | |
Tan | Characterizing the Role of Long Non-Coding RNA CAN3 in Colorectal Cancer | |
Piehlmaier | Validation and functional characterization of a prognostic 4-miRNA signature in Glioblastoma | |
Morin | Safety of genome editing: development of a fluorescent model system to investigate reducing off-target genome edits by base editors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) |